Originally Aired: January 30, 2020
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
Accelerating research while minimizing workloads has been the driving force behind multiplexing laboratory and clinical assays. Moreover, multiplexed immunoassays can support the successful scale-up of translational research through rapid and reproducible biomarker quantification. Join us for this GEN webinar, where we will examine real-world examples that illustrate how multiomic biomarker assessment can play a pivotal role in the development of new potential therapeutics for cardiovascular disease. Applications discussed will include how biomarker screening has been successfully applied to identify potential novel biofluid-based biomarkers for Parkinson’s Disease in a variety of clinical samples. This webinar has been designed to provide key insights into how multiplexing can accelerate biomarker discovery in both drug development and clinical applications.
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
Director of Assay
Elnaz Atabakhsh, PhD
Senior Product Manager
Multiplex Assays, Abcam
Paul Wylie, PhD
Director of Multiplex